Breast MRI Spectroscopy, Department of Defense (DOD)
Our aim is to perform MR Spectroscopy (MRS) on 150 patients at the end of their clinically
indicated routine breast MRI guided biopsy and breast MRI guided needle localization
examination using a software package from General Electric Medical Systems (Milwaukee,WI).
This will add time to the routine examination but will not involve additional injections of
contrast. We will analyze the spectroscopic data to determine if benign lesions can be
reliably differentiated from malignant ones. The MR Spectroscopy (MRS) will be administered
at Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY,NY 10021.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
to determine if spectroscopy of the breast can be performed and can be functional in a clinical environment for breast lesions _> 1centimeter
conclusion of study
No
Sandra Brennan, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
05-101
NCT00582569
February 2006
May 2013
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |